Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 5/2013

01-10-2013 | Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Blockade of the Renin-Angiotensin System in Hypertensive Patients with Atherosclerotic Renal Artery Stenosis

Authors: Faical Jarraya, Menno Pruijm, Gregoire Wuerzner, Michel Burnier

Published in: Current Hypertension Reports | Issue 5/2013

Login to get access

Abstract

Renin angiotensin system (RAS) blockers are generally considered as contraindicated when an atheromatous renal artery stenosis (ARAS) is diagnosed. The main reason is the fear of inducing renal ischemia and, hence, accelerating renal fibrosis and the progression towards end stage renal disease, albeit RAS blocker have been shown to be highly effective in controlling blood pressure. Part of the solution came by the development of the revascularization. There is now growing evidence showing no superiority of angioplasty over medical treatment on cardiovascular events and mortality, renal function and blood pressure control. Hence, RAS blockers resurfaced based on their proven beneficial effects on blood pressure control and cardiovascular prevention in high risk atherosclerotic patients. Thus, RAS blockers belong today to the standard treatment of hypertensive patients with ARAS. However they were not systematically prescribed in trials focusing on ARAS. The ongoing CORAL trial will give us further information on the place of this class of antihypertensive drugs in patients with ARAS.
Literature
1.
Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population–based study. J Vasc Surg. 2002;36:443–51.PubMedCrossRef
2.
Hansen KJMD. Prevalence of ischemic nephropathy in the atherosclerotic population. Am J Kidney Dis. 1994;24(4):615–21.PubMed
3.
Kalra PA, Guo H, Kausz AT, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005;68:293–301.PubMedCrossRef
4.
Wright JR, Shurrab AE, Cooper A, et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol. 2005;16:2746–53.PubMedCrossRef
5.
Johansson M, Herlitz H, Jensen G, et al. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. J Hypertens. 1999;17:1743–50.PubMedCrossRef
6.
Isles C, Main J, O’Connell J, et al. Survival associated with renovascular disease in Glasgow and Newcastle: a collaborative study. Scott Med J. 1990;35:70–3.PubMed
7.
Wright JR, Shurrab AE, Cheung C, et al. A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis. 2002;39:1153–61.PubMedCrossRef
8.
9.
Mui KW, Sleeswijk M, van den Hout H, et al. Incidental renal artery stenosis is an independent predictor of mortality in patients with peripheral vascular disease. J Am Soc Nephrol. 2006;17:2069–74.PubMedCrossRef
10.
Pillay WR, Kan YM, Crinnion JN, Wolfe JH. Prospective multicentre study of the natural history of atherosclerotic renal artery stenosis in patients with peripheral vascular disease. Br J Surg. 2002;89:737–40.PubMedCrossRef
11.
Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001;60:1490–7.PubMedCrossRef
12.
Rocha-Singh KJ, Eisenhauer AC, Textor SC, et al. Atherosclerotic Peripheral Vascular Disease Symposium II: Intervention for renal artery disease.et al. Circulation. 2008;118:2873–8.PubMedCrossRef
13.
Textor SC. Atherosclerotic renal artery stenosis : overtreated but undertreated ? J Am Soc Nephrol. 2008;19:656–9.PubMedCrossRef
14.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.PubMedCrossRef
15.
•• Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006;152:59–66. CORAL is a randomized clinical trial contrasting optimum medical therapy alone including a rennin angiotensin system blocker to stenting with optimum medical therapy on a composite cardiovascular and renal end point: cardiovascular or renal death, myocardial infarction, hospitalization for congestive heart failure, stroke, doubling of serum creatinine, and need for renal replacement therapy. This study will clearly test the need of a RAS blocker in these patients and will test PTRA on top.PubMedCrossRef
16.
Alcazar JM, Marin R, Gomez-Campdera F, et al. Clinical characteristics of ischaemic renal disease. Nephrol Dial Transplant. 2001;16:74–7.PubMedCrossRef
17.
Rigatelli G, Rigatelli G. Predictors of renal artery stenosis in patients with normal renal function undergoing coronary angiography. Minerva Cardioangiol. 2006;54:145–9.PubMed
18.
Edwards MS, Craven TE, Burke GL, et al. Renovascular disease and the risk of adverse coronary events in the elderly: a prospective, population-based study. Arch Intern Med. 2005;165:207–13.PubMedCrossRef
19.
Losito A, Fagugli RM, Zampi I, et al. Comparison of target organ damage in renovascular and essential hypertension. Am J Hypertens. 1996;9:1062–7.PubMedCrossRef
20.
Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med. 1979;301:1273–6.PubMedCrossRef
21.
Iantorno M, Pola R, Schinzari F, et al. Association between altered circadian blood pressure profile and cardiac end-organ damage in patients with renovascular hypertension. Cardiology. 2003;100:114–9.PubMedCrossRef
22.
Conlon PJ, Athirakul K, Kovalik E, et al. Survival in renal vascular disease. J Am Soc Nephrol. 1998;9:252–6.PubMed
23.
24.
Chade AR, Rodriguez-Porcel M, Grande JP, et al. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation. 2002;106:1165–71.PubMedCrossRef
25.
Heyman SN, Roger G, Evans RG, et al. Cellular adaptive changes in AKI: mitigating renal hypoxic injury. Nephrol Dial Transplant. 2012;27:1721–8.PubMedCrossRef
26.
Prasad PV, Edelman RR, Epstein FH. Noninvasive evaluation of intrarenal oxygenation with BOLD MRI. Circulation. 1996;94:3271–5.PubMedCrossRef
27.
Pruijm M, Hofmann L, Vogt B, et al. Renal tissue oxygenation in essential hypertension and chronic kidney disease. Int J Hypertens. 2013;2013:696598.PubMed
28.
• Textor SC, Glockner JF, Lerman LO, et al. The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. J Am Soc Nephrol. 2008;19:780–8. BOLD-MRI detects changes in tissue deoxyhemoglobin during maneuvers that affect oxygen consumption, therefore, this technique was used to diagnose renal artery stenosis in 50 kidneys from 25 subjects. BOLD-MRI studies suggest that renal tissue oxygenation is maintained over a wide range of renal artery stenosis.PubMedCrossRef
29.
• Gloviczki ML, Glockner JF, Crane JA, et al. Blood oxygen level-dependent magnetic resonance imaging identifies cortical hypoxia in severe renovascular disease. Hypertension. 2011;58:1066–72. BOLD-MRI may provide a marker for identification of hypoxic parenchymal injury that is particularly important for long term management of renovascular disease. This study demonstrates decreased cortical tissue oxygenation measured by BOLD MRI in progressively more severe renovascular occlusive disease. Oxygenation in both the cortex and medulla was preserved in “moderate” ARAS, despite measurable loss of kidney volume and blood flow. It highlights that compensation for impaired blood flow is limited and that the most severe renal arterial occlusive lesions produce loss of function with cortical hypoxia detectable by BOLD MRI.PubMedCrossRef
30.
Juillard L, Lerman LO, Kruger DG, et al. Blood oxygen level-dependent measurement of acute intra-renal ischemia. Kidney Int. 2004;65:944–50.PubMedCrossRef
31.
Textor SC, Misra S, Oderich GS. Percutaneous revascularization for ischemic nephropathy: the past, present, and future. Kidney Int. 2013;83:28–40.PubMedCrossRef
32.
Plouin PF, Chatellier G, Darne B, et al. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs. Angioplastie (EMMA) Study Group. Hypertension. 1998;31:823–9.PubMedCrossRef
33.
Webster J, Marshall F, Abdalla M, et al. Randomised comparison of percutaneous angioplasty vs. continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens. 1998;12:329–35.PubMedCrossRef
34.
van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med. 2000;342:1007–14.PubMedCrossRef
35.
Nordmann AJ, Woo K, Parkes R, Logan AG. Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta-analysis of randomized controlled trials. Am J Med. 2003;114:44–50.PubMedCrossRef
36.
La Batide-Alanore A, Azizi M, Froissart M, et al. Split renal function outcome after renal angioplasty in patients with unilateral renal artery stenosis. J Am Soc Nephrol. 2001;12:1235–41.PubMed
37.
• The ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361:1953–62. This is a multicenter, prospective randomized study comparing renal stenting with medical therapy to medical therapy alone. In contrast to other studies, in addition to having RAS of > 50 %, treating clinicians had to be uncertain as to whether the potential subjects would benefit from revascularization. These data emphasize the success and stability of medical therapy alone for many patients with ARAS for several years. More than 40 % of the patients were in the category of 50 % to 70 % stenosis, which likely diluted the power of this trial.CrossRef
38.
Bax L, Woittiez AJ, Kouwenberg HJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function. Ann Intern Med. 2009;150:840–8.PubMedCrossRef
39.
Marcantoni C, Zanoli L, Rastelli S, et al. Effect of renal artery stenting on left ventricular mass: a randomized clinical trial. Am J Kidney Dis. 2012;60:39–46.PubMedCrossRef
40.
Rossi GP, Seccia TM, Miotto D, et al. The Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS) study: rationale and study design. J Hum Hypertens. 2012;26:507–16.PubMedCrossRef
41.
•• Kumbhani DJ, Bavry AA, Harvey JE, et al. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J. 2011;161:622–30. This meta-analysis includes six randomized controlled trials and accounts for 1208 patients and compares PTRA revascularization in addition to medical therapy vs. medical management alone in patients with ARAS. At a mean follow-up of 29 months, there was no benefit of PTRA compared with the medical management arm on blood pressure, all-cause mortality, congestive heart failure, stroke, or worsening renal function.PubMedCrossRef
42.
• Wilensky R, Gertz Z. Study of Percutaneous Renal Artery Intervention for Patient With Heart Failure (STRETCH). ClinicalTrials.gov Web site. http://​clinicaltrials.​gov/​ct2/​show/​NCT01403714?​term=​NCT01403714&​rank=​1. Accessed May 1, 2013. This study will address the role of percutaneous renal intervention for a hemodynamically significant renal artery stenosis in patients with heart failure exacerbations not attributable to declining left ventricular function, valvular disease, acute coronary syndrome, or heart transplant rejection. This randomized trial will enroll about 200 patients and with hemodynamically significant renal artery stenoses will be randomized to stent implantation or medical therapy.
43.
Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension : I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:347–79.PubMedCrossRef
44.
Wiesel P, Mazzolai L, Nussberger J, Pedrazzini T. Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension. 1997;29:1025–30.PubMedCrossRef
45.
46.
Postma CT, van der Steen PH, Hoefnagels WH. The captopril test in the detection of renovascular disease in hypertensive patients. Arch Intern Med. 1990;150(3):625–8.PubMedCrossRef
47.
Postma CT, van Oijen AH, Barentsz JO, et al. The value of tests predicting renovascular hypertension in patients with renal artery stenosis treated by angioplasty. Arch Intern Med. 1991;151:1531–5.PubMedCrossRef
48.
Roubidoux MA, Dunnick NR, Klotman PE, et al. Renal vein renins: inability to predict response to revascularization in patients with hypertension. Radiology. 1991;178:819–22.PubMed
49.
Simon G, Coleman CC. Captopril-stimulated renal vein renin measurements in the diagnosis of atherosclerotic renovascular hypertension. Am J Hypertens. 1994;7:1–6.PubMed
50.
Strong CG, Hunt JC, Sheps SG, et al. Renal venous renin activity. Enhancement of sensitivity of lateralization by sodium depletion. Am J Cardiol. 1971;27:602–11.PubMedCrossRef
51.
De Bruyne B, Manoharan G, Pijls NH, et al. Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol. 2006;48:1851–5.PubMedCrossRef
52.
Tanemoto M, Suzuki T, Abe M, et al. Hemodynamic index of atheromatous renal artery stenosis for angioplasty. Clin J Am Soc Nephrol. 2009;4:651–5.PubMedCrossRef
53.
Brown JJ, Davies DL, Morton JJ, et al. Mechanism of renal hypertension. Lancet. 1976;1(7971):1219–21.PubMedCrossRef
54.
55.
Horovitz ZP, Antonaccio MJ, Rubin B, Panasevich RE. Influence of various antihypertensive agents on lifespan of renal hypertensive rats. Br J Clin Pharmacol. 1979;7 suppl 2:243S–8.PubMedCrossRef
56.
Rubin B, Antonaccio MJ, Goldberg ME, et al. Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats. Eur J Pharmacol. 1978;51:377–88.PubMedCrossRef
57.
Hackam DG, Spence JD, Garg AX, Textor SC. Role of rennin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007;50:998–1003.PubMedCrossRef
58.
Dussaule JC, Michel JB, Auzan C, et al. Effect of antihypertensive treatment on the left ventricular isomyosin profile in one-clip, two kidney hypertensive rats. J Pharmacol Exp Ther. 1986;236:512–8.PubMed
59.
Matsubara BB, Matsubara LS, Franco M, et al. The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension. Int J Exp Pathol. 1999;80:97–104.PubMedCrossRef
60.
Jalil JE, Janicki JS, Pick R, Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril. Am J Hypertens. 1991;4:51–5.PubMed
61.
Hilgers KF, Hartner A, Porst M, et al. Angiotensin II type1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation. Circulation. 2001;104:1436–40.PubMedCrossRef
62.
Schwietzer G, Oelkers W. The antihypertensive effect of captopril in severe essential, renovascular, renal and transplant renovascular hypertension. Klin Wochenschr. 1982;60:839–46.PubMedCrossRef
63.
Hodsman GP, Brown JJ, Cumming AM, et al. Enalapril (MK421) in the treatment of hypertension with renal artery stenosis. Br Med J. 1983;287:1413–7.CrossRef
64.
Textor SC, Tarazi RC, Novick AC, et al. Regulation of renal hemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril. Am J Med. 1984;76(5B):29–37.PubMedCrossRef
65.
Reams GP, Bauer JH. Enalapril versus triple-drug therapy in the treatment of renovascular hypertension. Drugs. 1985;30 suppl 1:59–69.PubMedCrossRef
66.
Franklin SS, Smith RD. A comparison of enalapril plus hydrochlorothiazide with standard triple therapy in renovascular hypertension. Nephron. 1986;44 suppl 1:73–82.PubMedCrossRef
67.
Tullis MJ, Caps MT, Zierler RE, et al. Blood pressure, antihypertensive medication, and atherosclerotic renal artery stenosis. Am J Kidney Dis. 1999;33:675–81.PubMedCrossRef
68.
Losito A, Errico R, Santirosi P, et al. Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant. 2005;20:1604–9.PubMedCrossRef
69.
•• Hackam DG, Duong-Hua ML, Mamdani M, et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J. 2008;156:549–55. A population-based cohort comprising 3,570 patients with renovascular disease, where 53 % were prescribed angiotensin inhibitors. This study emphasized the high vascular risk of renal vascular disease and suggesedt that angiotensin inhibitors may improve cardiovascular and renal prognosis in this setting at the expense of acute renal toxicity, stressing renal function parameters that should be assiduously followed.PubMedCrossRef
70.
•• Gloviczki ML, Glockner JF, Lerman LO, et al. Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis. Hypertension. 2010;55:961–6. This study compared stenotic and contralateral kidneys regarding volume, tissue perfusion; blood flow measured by multidetector computed tomography, and BOLD- magnetic resonance values in the cortex and medulla in 14 patients with unilateral stenosis and in 14 essential hypertensive patients. It indicates that, although stenosis reduced blood flow and volume, cortical and medullary oxygenation were preserved under these conditions; however, stenosis is not severe in this study (mean 71 ± 5.5%).PubMedCrossRef
71.
Lerman LO, Chade AR. Angiogenesis in the kidney: a new therapeutic target? Curr Opin Nephrol Hypertens. 2009;18:160–5.PubMedCrossRef
Metadata
Title
Blockade of the Renin-Angiotensin System in Hypertensive Patients with Atherosclerotic Renal Artery Stenosis
Authors
Faical Jarraya
Menno Pruijm
Gregoire Wuerzner
Michel Burnier
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 5/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-013-0376-x

Other articles of this Issue 5/2013

Current Hypertension Reports 5/2013 Go to the issue

Pediatric Hypertension (JT Flynn, Section Editor)

Primary Hypertension in Childhood

Pediatric Hypertension (JT Flynn, Section Editor)

Determinants of Neonatal Blood Pressure

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Potential Benefits of Rho-kinase Inhibition in Arterial Hypertension

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Hypertension after Kidney Transplantation: A Pathophysiologic Approach

Hypertension Management and Antihypertensive Drugs (HM Siragy and B Waeber, Section Editors)

Endothelin Antagonism and Its Role in the Treatment of Hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits